AIDS research. Did Merck's failed HIV vaccine cause harm? - PubMed (original) (raw)

AIDS research. Did Merck's failed HIV vaccine cause harm?

Jon Cohen. Science. 2007.

No abstract available

PubMed Disclaimer

Similar articles

• Merck's HIV vaccine flop brings vectors under closer scrutiny.
  Ledford H. Ledford H. Nat Biotechnol. 2008 Jan;26(1):3-4. doi: 10.1038/nbt0108-3. Nat Biotechnol. 2008. PMID: 18182999 No abstract available.
• AIDS/HIV. A STEP into darkness or light?
  Moore JP, Klasse PJ, Dolan MJ, Ahuja SK. Moore JP, et al. Science. 2008 May 9;320(5877):753-5. doi: 10.1126/science.1154258. Science. 2008. PMID: 18467578 No abstract available.
• AIDS research. Trials of NIH's AIDS vaccine get a yellow light.
  Cohen J, Lester B. Cohen J, et al. Science. 2007 Dec 21;318(5858):1852. doi: 10.1126/science.318.5858.1852a. Science. 2007. PMID: 18096778 No abstract available.
• Identifying barriers to participation in prophylactic HIV-1 vaccine trials.
  Peters BS. Peters BS. Int J STD AIDS. 2006 Feb;17(2):73. doi: 10.1258/095646206775455784. Int J STD AIDS. 2006. PMID: 16464264 Review. No abstract available.
• What should South African HIV vaccine trials do about social harms?
  Milford C, Barsdorf N, Kafaar Z. Milford C, et al. AIDS Care. 2007 Oct;19(9):1110-7. doi: 10.1080/09540120701335212. AIDS Care. 2007. PMID: 18058395 Review.

Cited by

• Challenges for Vaccinologists in the First Half of the Twenty-First Century.
  Thomas S, Abraham A, Callaghan PJ, Rappuoli R. Thomas S, et al. Methods Mol Biol. 2022;2410:3-25. doi: 10.1007/978-1-0716-1884-4_1. Methods Mol Biol. 2022. PMID: 34914040
• CD8 T cell cross-reactivity networks mediate heterologous immunity in human EBV and murine vaccinia virus infections.
  Cornberg M, Clute SC, Watkin LB, Saccoccio FM, Kim SK, Naumov YN, Brehm MA, Aslan N, Welsh RM, Selin LK. Cornberg M, et al. J Immunol. 2010 Mar 15;184(6):2825-38. doi: 10.4049/jimmunol.0902168. Epub 2010 Feb 17. J Immunol. 2010. PMID: 20164414 Free PMC article.
• Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites.
  Yu B, Fonseca DP, O'Rourke SM, Berman PW. Yu B, et al. J Virol. 2010 Feb;84(3):1513-26. doi: 10.1128/JVI.01765-09. Epub 2009 Nov 25. J Virol. 2010. PMID: 19939935 Free PMC article.
• Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates.
  Geisbert TW, Daddario-Dicaprio KM, Lewis MG, Geisbert JB, Grolla A, Leung A, Paragas J, Matthias L, Smith MA, Jones SM, Hensley LE, Feldmann H, Jahrling PB. Geisbert TW, et al. PLoS Pathog. 2008 Nov;4(11):e1000225. doi: 10.1371/journal.ppat.1000225. Epub 2008 Nov 28. PLoS Pathog. 2008. PMID: 19043556 Free PMC article.
• Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration.
  Bansal A, Jackson B, West K, Wang S, Lu S, Kennedy JS, Goepfert PA. Bansal A, et al. J Virol. 2008 Jul;82(13):6458-69. doi: 10.1128/JVI.00068-08. Epub 2008 Apr 30. J Virol. 2008. PMID: 18448544 Free PMC article. Clinical Trial.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Other Literature Sources

  • The Lens - Patent Citations Database